We're not for everyone.
We’re for those who believe uniting evidence and access improves patient outcomes.
We connect specialty therapies to the patients who need them most by delivering modern, customized solutions in access, safety, and evidence generation.
Accelerating Patient Outcomes for Biopharma
We partner with biopharma to modernize evidence development and patient access pathways, ensuring therapies are safe, effective, and available to those who need them. We transform how therapies reach and serve patients by integrating real-world evidence, risk management, and a deep understanding of the patient journey. Our customized solutions leverage unrivaled expertise, real-world data, and the latest technologies to demonstrate long-term product value and support better patient outcomes.
Explore Biopharma Solutions
Purpose-built solutions to deliver the evidence required to inform stakeholder decision making.
Evidence Development
Our expert-led evidence generation solutions are designed to deliver the critical data required to inform stakeholder decision-making at every step. From modernized study designs and execution to late-stage research, we develop comprehensive real-world evidence strategies that align with the expectations of patients, providers, regulators, and payers. We guide you through the complexities of approval, commercialization, and the demonstration of long-term product value for your therapies.
Safety & Risk Management
We provide comprehensive, tailored drug safety and global risk management solutions that are sophisticated, tech-enabled, and regulatory compliant. Drawing on decades of experience, our strategies are crafted to meticulously address the benefit/risk profile of specialty therapies and ensure every decision is expertly informed. As a recognized leader in Risk Evaluation and Mitigation Strategies (REMS), we deliver an integrated approach to pharmacovigilance and drug safety services that optimizes your program and gives you peace of mind.
Patient Access
Our targeted approach combines high-tech and high-touch care to provide exceptional patient access, affordability, and adherence solutions. By building a seamless and scalable experience, we strategically address complex payer and insurance hurdles, ensuring your therapy reaches the patients who need it most and solidifying long-term product success and value creation.
Expertise that unites real-world evidence and patient access to improve outcomes.
UBC brings together seasoned professionals specializing in specialty therapies across risk management, evidence development, and patient access. Providing collaborative, expert-driven solutions tailored to your program, we are driven by a commitment to overcoming the barriers between your therapy and the patients that need it most. We leverage unrivaled expertise, real-world data and the latest technologies to provide the insights you need to mitigate risk, demonstrate long-term product value, ensure access, and support better patient outcomes.
Explore Biopharma Services
Purpose-built solutions to deliver the evidence required to inform stakeholder decision making.
Evidence Development
Expert-led evidence generation solutions to guide you through every step of program design and delivery, from modernized study designs to late-stage research. We develop real-world evidence strategies that align with the expectations of patients, providers, regulators, and payers — and help you navigate the complexities of approval, commercialization, and delivery of long-term outcomes.
Safety & Risk Management
Comprehensive, tailored drug safety and global risk management solutions that are sophisticated, tech-enabled, and regulatory compliant. Our decades of experience drive strategies to address the benefit/risk profile of specialty therapies, optimize pharmacovigilance, and ensure every decision is informed.
Patient Access
A targeted approach that integrates high-tech and high-touch care for exceptional patient access, affordability, and adherence solutions. Purpose-built to fit unique patient health journeys, our patient access support addresses payer and insurance hurdles while building a seamless, scalable experience and enhancing patient outcomes.
Insights
Regulatory Submissions with Real-World Evidence: Highlights from the Joint Duke Margolis Institute and FDA Public Meeting
As Real World Evidence (RWE) continues to shape regulatory decision-making, the FDA and Duke Margolis Institute convened a public meeting to share successes, challenges, and lessons learned in RWE submissions. With over 4,000 attendees, the event spotlighted case studies, data feasibility, and the evolving role of RWE in labeling, post-marketing commitments, and registrational trials. Learn how sponsors are partnering with regulators to modernize study design and advance global RWE standards.
News
UBC Launches New Pharmacovigilance Reporting Capabilities
UBC launches new RxLogix pharmacovigilance reporting platform to enhance drug safety capabilities with advanced aggregate reporting, real-time analytics, and reduced regulatory risk for biopharmaceutical companies.
Events
World Drug Safety Congress Europe 2025
Meet with UBC’s safety and risk management team at World Drug Safety Congress Europe for unmatched pharmacovigilance insights.
